Invasive ductal carcinoma (IDC) has a strong overall survival rate, particularly when caught early. The five-year relative survival rate for localized breast cancer, the category that includes most IDC diagnoses, is effectively 100%. Because IDC accounts for roughly 70-80% of all invasive breast cancers, general breast cancer survival statistics closely reflect IDC outcomes. Those numbers shift significantly based on how far the cancer has spread at diagnosis, the biological subtype of the tumor, and how the cancer responds to treatment.
Five-Year Survival Rates by Stage
Stage at diagnosis is the single biggest factor in survival. The National Cancer Institute’s SEER database, which tracks cancer outcomes across the U.S., reports these five-year relative survival rates for female breast cancer based on 2016-2022 data:
- Localized (cancer confined to the breast): 100%
- Regional (spread to nearby lymph nodes): 87.5%
- Distant (spread to other organs): 33.8%
A “relative” survival rate compares people with cancer to people of the same age without cancer, so a rate of 100% means women with localized breast cancer are surviving at the same rate as the general population. The good news is that the majority of IDC cases are diagnosed at the localized stage, when the prognosis is excellent.
Ten-Year Survival
Longer-term data tells a slightly different story. A 2022 study published in the Journal of the National Cancer Institute, which followed more than 32,000 U.S. breast cancer patients, found that the estimated 10-year overall survival for IDC is 73%. For estrogen receptor-positive IDC specifically, the most common subtype, that number rises to 77%. The gap between five-year and ten-year figures reflects the reality that some breast cancers can recur years after initial treatment, which is why ongoing monitoring matters well beyond the five-year mark.
How Tumor Subtype Affects Outcomes
Not all invasive ductal carcinomas behave the same way. The cancer’s molecular profile, specifically whether it has hormone receptors or a protein called HER2 on its surface, plays a major role in both treatment options and survival.
Hormone receptor-positive IDC (meaning the cancer grows in response to estrogen or progesterone) tends to have the best prognosis. These tumors respond well to hormone-blocking therapies that can be taken for years after initial treatment, which helps prevent recurrence. HER2-positive cancers were once considered more aggressive, but targeted therapies developed over the past two decades have dramatically improved outcomes for this group.
Triple-negative breast cancer, which lacks hormone receptors and HER2, has notably lower survival rates. The five-year relative survival for triple-negative cases breaks down as 92% for localized disease, 67% for regional spread, and 15% for distant metastasis, with an all-stages-combined rate of 78%. These cancers have fewer targeted treatment options and tend to grow more quickly, though newer immunotherapy combinations have begun to improve results.
Survival by Age at Diagnosis
Age at diagnosis has a modest but real effect on outcomes. Overall five-year survival rates for breast cancer by age group are:
- Younger than 45: 88%
- Ages 45 to 54: 91%
- Ages 55 to 64: 91%
- Ages 65 to 74: 92%
- 75 and older: 86%
The slightly lower rate in younger women reflects the fact that breast cancers diagnosed before age 45 are more likely to be aggressive subtypes, including triple-negative and high-grade tumors. Women over 75 see a dip partly because other health conditions can complicate treatment. The middle age groups, which are most likely to be diagnosed through routine screening, benefit from catching tumors at earlier, more treatable stages.
Recurrence Risk After Treatment
Survival statistics capture outcomes from diagnosis, but many people with IDC also want to understand the chance of cancer coming back after successful treatment. Most local recurrences happen within the first five years after a lumpectomy. When lumpectomy is combined with radiation therapy, the chance of recurrence within 10 years falls to between 3% and 15%.
Lymph node involvement at the time of original surgery is one of the strongest predictors. If no cancer was found in the lymph nodes during surgery, the five-year recurrence risk is about 6%. If the lymph nodes were positive for cancer, that risk jumps to roughly 25%. This is one reason doctors recommend more aggressive follow-up treatment, such as chemotherapy or extended hormone therapy, for patients with lymph node involvement.
Hormone receptor-positive IDC carries a unique pattern: while it tends to have better short-term survival, it can recur 10, 15, or even 20 years after diagnosis. This is why many patients with this subtype take hormone-blocking medication for five to ten years and continue with regular imaging well beyond the typical five-year surveillance window.
What These Numbers Mean for You
Survival statistics describe large populations, not individual outcomes. Your own prognosis depends on a combination of factors: the stage and grade of your tumor, its molecular subtype, how completely it was removed during surgery, and how well it responds to any additional treatment. Two people with the same stage of IDC can have very different outcomes based on these variables.
The overall trend is clearly positive. Breast cancer survival rates have been climbing steadily for decades, driven by earlier detection through screening and a growing arsenal of targeted treatments. The numbers cited here reflect patients diagnosed years ago. People diagnosed today, with access to the latest therapies, may fare even better than these statistics suggest.